Many biotechs in the antibody-drug conjugate (ADC) space pulled back throughout much of 2024, offsetting a late-2023/early-2024 rally. Immunome (NASDAQ: IMNM ) was one such company caught up in that swoon and fall, despite my buy rating in April 2024, whereScientist and trader of biotech stock. Focus on trading around events such as trial results and NDA/BLA approvals. Also covering companies in industries regulated by the FDA. Articles present my opinion on stocks, but don't constitute investment advice.An ...